5670 Organometallics, Vol. 24, No. 23, 2005
Spencer et al.
(CDCl3): δ 172.9, 171.6, 139.9, 139.3, 132.1, 131.7, 130.7, 130.1,
128.5, 127.6, 123.6, 121.7, 57.1. (C15H12N2O); m/z 237 (MH+,
100%). Alternatively, the method of Stafford et al. was used.6a
1-Methyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one, 2a.6b
The product from the previous step (0.50 g, 2.12 mmol) was
stirred with sodium hydride (60% suspension in paraffin oil,
0.12 g, 3.00 mmol) in DMF (10 mL) for 0.5 h under Ar.
Thereafter, iodomethane (264 µL, 4.24 mmol) was added and
the reaction was monitored by TLC until complete. After
dilution with ethyl acetate (30 mL), the organic layer was
washed with brine (2 × 30 mL) and water (20 mL), dried
(MgSO4), filtered, and concentrated in vacuo. The product was
obtained as a solid after column chromatography (7:3 ethyl
acetate/pentane) (0.47 g, 48%). 1H NMR (CDCl3): δ 7.63-7.16
(9H, m), 4.83 (1H, d), 3.81 (1H, d), 3.41 (3H, s). 13C NMR
(CDCl3): δ 170.8, 170.5, 144.5, 139.2, 131.7, 130.9, 130.7, 129.9,
128.6, 124.1, 121.4, 57.4, 35.2 (C16H14N2O); m/z 251 (MH+,
100%).
1-Benzyl-5-phenyl-1H-1,4-benzodiazepin-2(3H)-one, 2b.
This was made on a 0.5 mmol scale (0.163 g, 55%) according
to the method used for the synthesis of 2a except that benzyl
bromide was used instead of methyl iodide. 1H NMR (CDCl3):
δ 7.47-7.06 (14H, m), 5.63 (1H, d, J(HH) ) 15.3 Hz), 4.89 (1H,
d, J(HH) ) 10.2 Hz), 4.79 (1H, d, J(HH) )15.3 Hz), 3.90 (1H,
d, J(HH) ) 10.2 Hz). 13C NMR (CDCl3): δ 171.0, 169.8, 142.6,
139.2, 137.2, 131.6, 130.9, 130.7, 130.6, 129.9, 129.0, 128.5,
127.8, 127.6, 124.8, 122.7, 57.4, 50.0 (C22H18N2O); m/z 327
(MH+, 100%).
trend was observed for the coupling of n-butylacrylate
with 4-trifluoromethylbromobenzene (98%, 3a; 94%, 3b;
69%, 4a, respectively, entries 10-12). As with the
Suzuki coupling reactions (Table 3), activated chlorides
were poor coupling partners and yields were worse at
elevated temperatures (entries 13 and 14, Table 5). In
a few cases isolated yields were obtained and were in
agreement with those determined by GC (entry 1, Table
4, and entry 2, Table 5).
Conclusion
We have demonstrated that the 1,4-benzodiazepine
system is a modular and versatile ligand for the
preparation of palladium complexes. Air-stable palla-
dacycles 3a-c and the “SCN pincer”13 palladacycle 6f
were prepared by C-H activation reactions, and the
reaction of 3a-c with PPh3 led to the monomeric 4a-
c. The novel monomeric coordination complex 5d was
formed from the reaction of 2d with Na2PdCl4 or PdCl2-
(MeCN)2.14 Complexes 3a and 6f displayed moderate
activity in Suzuki coupling reactions, whereas 3a, 3c,
and 4a had moderate activity in Heck couplings, which
may be due to poor catalyst longevity.3b Future studies
will be aimed at preparing 1,4-benzodiazepine-contain-
ing complexes to address this issue.
Benzyl 2-(2,3-dihydro-2-oxo-5-phenyl-1,4-benzodiazepin-
1-yl)acetate, 2c. This was made on a 1.9 mmol scale (0.364
g, 50%) according to the method used for the synthesis of 2a
except that benzyl bromoacetate was used instead of methyl
Experimental Section
General Procedures. All procedures were carried out in
air using commercial high-grade solvents (Fluka & Aldrich
Sureseal). Palladium salts were purchased from Aldrich and
used without further purification. Amino acids and coupling
1
iodide. H NMR (CDCl3): δ 7.61-7.20 (14H, m), 5.28 (2H, s),
4.85 (1H, d), 4.69 (1H, d), 4.53 (1H, d), 3.88 (1H, d). 13C NMR
(CDCl3): δ 171.0, 170.0, 169.2, 143.1, 135.6, 132.0, 131.0, 130.8,
130.0, 129.7, 128.9, 128.8, 128.6, 124.9, 121.5, 67.6, 56.8, 49.9
(C24H20N2O3); m/z 385 (MH+, 20%).
1
agents were purchased from Novabiochem. H, 13C{1H}, and
31P{1H} NMR spectra were recorded on a Bruker AC 300
spectrometer at 300, 75, and 120 MHz, respectively. Mass
spectra were carried out on a Waters ZQ spectrometer. Optical
activity measurements were recorded with a sodium lamp at
589 nM at 20 °C on an Optical Activity A10 polarimeter.
Elemental analyses were carried out by the Cambridge
University Microanalysis Service. Flash chromatography was
carried out on silica gel (Merck silica 60 (0.040-0.064 mm
grade)). Catalytic test reactions were performed as described
previously.12,15
3-(S)-(2-(Methylthio)ethyl)-5-phenyl-1H-1,4-benzodi-
azepin-2(3H)-one, 1d. 1d was made on a 6 mmol scale
according to the method used for 1a (0.99 g, 54%) except that
(L)-FMOC-Met-OH was used instead of FMOC-Gly-OH. 1H
NMR (CDCl3): δ 8.05 (1H, s), 7.53 (3H, m), 7.42 (4H, m), 7.15
(2H, m), 3.81 (1H, dd, J(HH) ) 5.4 Hz), 2.84 (1H, m), 2.53
(2H, m), 2.13 (3H, s).
3-(S)-1-Methyl-3-(2-(methylthio)ethyl)-5-phenyl-1H-1,4-
benzodiazepin-2(3H)-one, 2d. 1d was treated with sodium
hydride followed by iodomethane, on a 0.62 mmol scale, as for
the synthesis of 2b. The product was obtained as an oil (0.17
g, 85%) after flash chromatography (3:1 dichloromethane/ethyl
acetate): RD293 (+93.8°, CH2Cl2, c 1). 1H NMR (CDCl3): δ 7.61-
7.29 (8H, m), 7.17 (1H, m), 3.76 (1H, m), 3.40 (3H, s), 2.76-
2.43 (4H, m), 2.06 (3H, s). 13C NMR (CDCl3): δ 169.5, 167.6,
142.6, 137.7, 130.4, 129.3, 129.2, 128.6, 128.1, 127.2, 122.8,
120.2, 60.8, 34.1, 30.1, 29.7, 14.5 (C19H20N2OS); m/z 325 (MH+,
100%).
Synthesis. 5-Phenyl-1H-1,4-benzodiazepin-2(3H)-one,
1a. 2-Aminobenzophenone (1.18 g, 6.00 mmol), EEDQ (1.48
g, 6.00 mmol), and FMOC-Gly-OH (1.78 g, 6.00 mmol) were
combined in anhydrous THF (25 mL) and left to stir at room
temperature overnight. After dilution with ethyl acetate (40
mL) and successive washings with potassium hydrogen sulfate
solution (10%, 20 mL), saturated sodium hydrogen carbonate
(20 mL), and brine, the organic layer was dried (MgSO4),
filtered, and concentrated. The crude product was treated with
a 20% solution of diethylamine in acetonitrile (30 mL) at room
temperature for 2 h. After evaporation of the volatiles followed
by flash chromatography (70:30 ethyl acetate/hexane) an oil
3-(S)-(tert-Butylthio)methyl)-5-phenyl-1H-1,4-benzodi-
azepin-2(3H)-one, 1e. 1e was made on a 5.4 mmol scale
according to the method used for 1a (1.0 g, 60%) except that
(L)-FMOC-Cys(t-Bu)-OH was used instead of FMOC-Gly-OH.
1H NMR (CDCl3): δ 10.36 (1H, s), 7.53-7.00 (9H, m), 3.72 (1H,
t, J(HH) ) 6.6 Hz), 3.43 (2H, m), 1.34 (9H, s).
1
was obtained (0.99 g, 70%). H NMR (CDCl3): δ 8.65 (1H, s),
7.56-7.35 (7H, m), 7.19 (2H, m), 4.34 (2H, s). 13C NMR
3-(S)-(tert-Butylthio)methyl)-1-methyl-5-phenyl-1H-
1,4-benzodiazepin-2(3H)-one, 2e. 2e was made from 1e on
a 2.96 mmol scale according to the method used for 2a (0.40
g, 40%): RD293 (+93.0°, CH2Cl2, c 1). 1H NMR (CDCl3): δ 7.53-
7.02 (9H, m), 3.61 (1H, t, J(HH) ) 5.1 Hz), 3.33 (2H, m), 3.29
(3H, s), 1.23 (9H, s). 13C NMR (CDCl3): δ 170.3, 168.8, 144.0,
139.0, 131.8, 130.7, 130.1, 129.5, 128.6, 124.2, 121.7, 64.8, 42.7,
35.5, 31.4 (C21H24N2OS); m/z 353 (MH+, 25%).
(13) (a) Holton, R. A.; Nelson, R. V. J. Organomet. Chem. 1980, 201,
C35. (b) Ebeling, G.; Meneghetti, M. R.; Rominger, F.; Dupont, J.
Organometallics 2002, 21, 3221. (c) Dangel, B. D.; Godula, K.; Youn,
S. W.; Sezen, B.; Sames, D. J. Am. Chem. Soc. 2002, 124, 11856.
(14) For the formation of coordination complexes rather than
palladacycles when employing Na2PdCl4 as metallating agent, see (a)
Dunina, V. V.; Gorunova, O.; Kuz’mina, L. G.; Livantsov, M. V.;
Grishin, Y. K. Tetrahedron: Asymmetry 1999, 10, 3951. (b) Zhao, Y.;
Helliwell, M.; Joule, J. A. Arkivoc 2000, 1, 360.
(15) (a) Rosa, G. R.; Ebeling, G.; Dupont, J.; Monteiro, A. L. Synthesis
2003, 18, 2894. (b) Zim, D.; Gruber, A. S.; Ebeling, G.; Dupont, J.;
Monteiro, A. L. Org. Lett. 2000, 2, 2881.
Palladacycles [(L)PdCl]2 3a-c. Typically the ligand
2a-c was stirred with 0.9 equiv of Na2PdCl4 in EtOH (20 mL)